Video

Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

Author(s):

Richard S. Finn, MD

In Partnership With:

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Adam E. Singer, MD, PhD, of UCLA Health
September 13th 2024

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Adam E. Singer, MD, PhD, of UCLA Health
September 12th 2024

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

Ritu Salani, MD, director, Gynecologic Oncology, University of California Los Angeles
August 28th 2024

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer